Pharmaceuticals Hong Kong

Hong Kong Aminoglycosides Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong Aminoglycosides Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Product, By Route of Administration, By Application, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Buy the full report

Report snapshot

Hong Kong Aminoglycosides Market Analysis at a glance
Market size, 2025Researched figures come with the full report
Forecast, 2034Researched figures come with the full report
Growth (CAGR), 2025–2034Researched figures come with the full report
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, route of administration and application (see all)
Key playersPfizer Inc., AbbVie Inc., Teva Pharmaceutical, Zoetis, Inc, Kremoint Pharma Pvt. Ltd. and 2 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials13 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

The Hong Kong Aminoglycosides Market Analysis Executive Summary

Aminoglycosides are antibacterial agents that act against aerobic Gram-negative microorganisms in this group of antibiotics, the predominant mechanism of action involves binding to the 30S ribosomal subunit in order to inhibit protein synthesis in bacterial cells and hence, killing them. Some examples of aminoglycosides are streptomycin, gentamycin, tobramycin, and amikacin. These drugs are commonly injected because of their poor oral bioavailability and their use is restricted to severe infections due to side effects that include nephrotoxicity and ototoxicity. Nonetheless, aminoglycosides present certain risks and are even more important for treating multidrug-resistant bacteria and are often combined with other antibiotics to improve efficacy or counteract resistance mechanisms. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to CDC's 2019.

The drivers for the aminoglycosides market are increasing bacterial infections and the rising trend of antibiotic resistance Global support for health and awareness crusade enhances growth. However, it has some risks like high side effect profiles, lengthy approval procedures, and a fiercely competitive environment for the pharmaceutical industries. It is difficult to treat them due to poor oral bioavailability that restricts them to injectable preparations. The regulatory framework for clinical research and development is robust, while the insurance and cost analyses of effectiveness are mixed. In a word, it is a large market but not without challenges.

Hong Kong Aminoglycosides Market Dynamics

Market Growth Drivers

The higher frequency of bacterial infections, which leads to the need for effective antibiotics, the high incidence of respiratory diseases in which aminoglycosides play a vital role, the necessity to improve the diagnosis and treatment of many diseases; the increase in the number of patients, especially in the Asia-Pacific region, mainly due to the better development of the healthcare sector, continuing research activities to improve existing and develop new products containing aminoglycosides Besides, increased incidence of animal diseases and an increasing elderly population also boost the market.

Opportunity

The promising avenues that are expected to transform the prospects of aminoglycoside market in future are the growth in emerging economies like Asia-Pacific and Africa, partnerships between different pharma companies and research institutes for the discovery of new aminoglycosides, emerging focus on personalized drugs, increase in R and D by companies for introducing new forms, combination therapies, increasing focus on outpatient treatment, increasing use of generics and the use of smart technologies.

Market Restraints

Aminoglycosides have several drawbacks regarding their application and market expansion. Severe adverse effects including nephrotoxicity and ototoxicity place constraints on their use especially in certain demographics. The discover of new antibiotic-resistant bacteria neutralizes the use and therefore shifts focus to other modes of treatment. New formulation approval processes take a long duration to obtain thus preventing the market entry, competition among the pharmaceutical companies is high and this leads to price undercutting and decreased profitability margins. Their poor oral bioavailability limits the practical use of products to injections and thus reduces patient compliance. Further, economic volatility impacts the cost and availability, especially in a country with a constrained healthcare budget. Both these angles contribute towards the overall geography and restraint of the aminoglycosides market.

Competitive Landscape Aminoglycosides Market in Hong Kong

Key Players

Recent Developments

February 2024, Cipla gets approval to introduce antibiotic injection to treat UTIs in India, holds the patent for plazomicin sulfate, an intravenous aminoglycoside administered once daily.

Merger and Acquisition

In November 2025, Pfizer made a major move in the pharmaceutical industry by acquiring Nektar Therapeutics for $7.5 billion. This strategic acquisition strengthens Pfizer's antibiotic portfolio, with a specific emphasis on the aminoglycosides sector.

Healthcare Policies and Regulatory Landscape for Aminoglycosides Market in Hong Kong

Aminoglycosides in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 13 studies on Aminoglycosides that are recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

Policies promoting antibiotic stewardship and funding for research support the development of new formulations and improve market growth potential. Public health campaigns raise awareness about antibiotic resistance, driving demand for effective treatments. However, reimbursement for aminoglycosides varies by region and insurance provider, which can affect patient access. Cost-effectiveness evaluations and patient assistance programs are becoming more important as healthcare systems shift towards value-based care. Additionally, increased focus on antibiotic stewardship programs influences reimbursement policies, ensuring that effective treatments remain available. These factors collectively shape the accessibility and market dynamics of aminoglycosides.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Aminoglycosides right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Aminoglycosides in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

What segments does the Aminoglycosides market report cover?
The report splits the market by product (Gentamicin, Neomycin, Tobramycin, Amikacin and more), route of administration (Parenteral, Intra-mammary, Topical, Oral) and application (Respiratory Diseases, Skin Infections, Urinary Tract Infections (UTIs) and Pelvic Diseases, Veterinary Applications and more).
Who are the key players in the Aminoglycosides market?
Key players include Pfizer Inc., AbbVie Inc., Teva Pharmaceutical, Zoetis, Inc, Kremoint Pharma Pvt. Ltd. and Cipla Inc., among 7 companies the report profiles.
What is driving the Aminoglycosides market?
The higher frequency of bacterial infections, which leads to the need for effective antibiotics, the high incidence of respiratory diseases in which aminoglycosides play a vital role, the necessity to improve the diagnosis and treatment of many diseases; the increase in the number of patients, especially in the…
Who regulates Aminoglycosides in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on Aminoglycosides are running in Hong Kong?
13 studies are recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
How much research is published on Aminoglycosides?
PubMed lists 14,937 papers on Aminoglycosides added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on antibiotics and infectious diseases

See the topic